Accelmed
Dr. Alpert began working with Accelmed in 2011. Previously, she had served as Corporate Senior Vice President for Global Regulatory Affairs at Medtronic and Vice President of Regulatory Science at C.R. Bard. Prior to entering private industry, Dr. Alpert held a variety of management positions at the US FDA covering drugs, devices and radiological health, and foods. Notably, Dr. Alpert was Director of the Office of Device Evaluation from 1993-1999. Susan remains a member and was formerly Chair of the Board of the Society for Women’s Health Research, and has also served on the Board of the Food Drug Law Institute, the Medical Technology Leadership Forum, and Women Business Leaders of the U.S. Health Care Industry Foundation (WBL). She is also a Fellow and former Chair of the Regulatory Affairs Professional Society. Susan served on the Executive Committee of the Clinical Trials Transformation Initiative and served two terms on the Board of the Minnesota International Center.
Dr. Alpert completed her undergraduate degree at Barnard College, Columbia University in New York City, and is a Pediatric Infectious Disease clinician with a Ph.D. in Medical Microbiology from NYU and an M.D. from the University of Miami, who has practical experience in laboratory research and clinical trials.
This person is not in any offices
Accelmed
Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger. With its proven track record and large team of accomplished investment professionals, Accelmed’s vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel.